MedTrace Logo

Analgecine for the Treatment of Neuropathic Pain

NCT02633618 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2015-12-17

No results posted yet for this study

Summary

A randomized, open-label , positive drug controlled (Neurotropin,Japan organs Pharmaceutical Co., Ltd. ), multi-center study to evaluate Analgecine's efficacy and safety for the treatment of neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

BIOLOGICAL

Analgecine

Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.

BIOLOGICAL

Neurotropin

a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.

Sponsors & Collaborators

  • VanWorld Pharmaceutical (Rugao) Company Limited

    lead INDUSTRY

Principal Investigators

  • Lu-Ning Wang · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2005-12-31
Completion
2005-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633618 on ClinicalTrials.gov